Sana Biotechnology Inc. Common Stock (SANA)
Stock · NASDAQ · Health Care
$2.28as of 10/16/2026
Price chart
Active signals
SANA Signal Track Record
How signals performed across all stocks →What SANA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -1.4% | 47% | September 18, 2026 |
| Bollinger Band BreakdownActive now | 23 | +0.5% | 52% | September 8, 2026 |
| Bollinger Band Breakout | 22 | -6.6% | 41% | August 11, 2026 |
| 200-Day Moving Average TouchActive now | 7 | +17.1% | 57% | August 11, 2026 |
| Any 20-session window (baseline) | -4.9% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product,…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 142
- Website
- sana.com/
Fundamentals
- 1-day range
- $2.25$2.49
- Market cap
- $948.97M
- P/E (trailing)
- —
- P/E (forward)
- -4.09
- EPS (trailing)
- $-0.76
- Dividend yield
- —
- Beta
- 2.31
- Avg. volume
- 3.18M
Forecasts
7 analyst ratings
Sana Biotechnology Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SANASana Biotechnology Inc. Common Stock$2.27▼ 8.28%Market cap $948.97MP/E —$2.32$6.55
- ATTOAttovia Therapeutics Inc. Common Stock$13.73▼ 7.10%Market cap $928.90MP/E 0.00$14.23$28
- ODTXOdyssey Therapeutics Inc. Common Stock$17.17▼ 2.28%Market cap $1.04BP/E —$15.1$29.05
- SLDBSolid Biosciences Inc. Common Stock$5.53▼ 3.66%Market cap $857.50MP/E —$3.79$11.45
- REPLReplimune Group Inc. Common Stock$10.86▼ 7.57%Market cap $1.08BP/E —$1.5$16.33
- DBVTDBV Technologies S.A. American Depositary Shares$9.05▼ 0.66%Market cap $813.58MP/E —$1.57$4.5
- AURAAura Biosciences Inc. Common Stock$6.1▼ 3.79%Market cap $798.53MP/E —$4.73$9.54
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SANA Sana Biotechnology Inc. Common Stock | $948.97M | — | $2.27 | ▼ 8.28% | $2.32$6.55 |
| ATTO Attovia Therapeutics Inc. Common Stock | $928.90M | 0.00 | $13.73 | ▼ 7.10% | $14.23$28 |
| ODTX Odyssey Therapeutics Inc. Common Stock | $1.04B | — | $17.17 | ▼ 2.28% | $15.1$29.05 |
| SLDB Solid Biosciences Inc. Common Stock | $857.50M | — | $5.53 | ▼ 3.66% | $3.79$11.45 |
| REPL Replimune Group Inc. Common Stock | $1.08B | — | $10.86 | ▼ 7.57% | $1.5$16.33 |
| DBVT DBV Technologies S.A. American Depositary Shares | $813.58M | — | $9.05 | ▼ 0.66% | $1.57$4.5 |
| AURA Aura Biosciences Inc. Common Stock | $798.53M | — | $6.1 | ▼ 3.79% | $4.73$9.54 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Hans Edgar Bishop · October 5, 2026 · Grant8.7K
- PATEL DHAVALKUMAR DHIRAJLAL · August 27, 2026 · Tax Withholding41.2K @ $4.11
- PATEL DHAVALKUMAR DHIRAJLAL · August 26, 2026 · Option Exercise125.0K
- Hans Edgar Bishop · July 6, 2026 · Grant6.3K
- Yang Patrick Y · June 4, 2026 · Grant90.0K
- Robert Nelsen · June 4, 2026 · Grant90.0K
- Michelle Seitz · June 4, 2026 · Grant90.0K
- Alise Reicin · June 4, 2026 · Grant90.0K
- Rosiello Robert L. · June 4, 2026 · Grant90.0K
- Bilenker Joshua H. · June 4, 2026 · Grant90.0K
- Hans Edgar Bishop · June 4, 2026 · Grant90.0K
- Richard Mulligan · June 4, 2026 · Grant90.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 160.75M
- Total value held
- $460.98M
- Institutional holders
- 193
- Unknown37.43M
- Unknown25.00M
- Unknown14.24M
- Unknown10.54M
- Unknown10.22M
- Unknown7.43M
- Unknown6.61M
- Unknown4.18M
- Unknown4.00M
- Unknown3.20M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Sana Biotechnology Featured in Diabetes Treatment Analysis
Sana Biotechnology was the subject of a recent analysis titled 'A Shot At Diabetes,' which likely examines the company's potential in treating the condition. This coverage places the stock in the spotlight for investors watching biotech developments. The stock is currently trading near its support level, with an RSI indicating it may be oversold.
Sana Biotechnology Featured in Diabetes Treatment Analysis. Sana Biotechnology was the subject of a recent analysis titled 'A Shot At Diabetes,' which likely examines the company's potential in treating the condition. This coverage places the stock in the spotlight for investors watching biotech developments. The stock is currently trading near its support level, with an RSI indicating it may be oversold.